Fundraising Fox
/Companies
Sign in

Second Sight Medical Products

NASDAQ: VANI

Sylmar, US · Delaware corporation · 1 known investors

Find your way into Second Sight Medical Products

Sign up to see every warm intro you have to Second Sight Medical Products

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Second Sight Medical Products team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Vivani develops miniaturized, long-acting subdermal drug implants using its NanoPortal technology to deliver steady doses of medication over months, addressing medication adherence challenges in chronic disease. Its pipeline targets chronic weight management and type 2 diabetes with semaglutide-based implants.

BiotechHealthtechMedical Devices

Founders & leadership

AMALFRED MANN
ALFRED MANNCo-founder
RGROBERT GREENBERG
ROBERT GREENBERGCo-founder
ES
Edward SedoActing Chief Accounting Officer
SD
Scott DunbarActing CEO
KL
KATHY LONDONExecutive
AMAdam Mendelsohn
Adam MendelsohnCEO
AM
Aaron MendelsohnNamed on SEC filing

Board

GW
Gregg WilliamsBoard director
WL
WILLIAM LINKBoard director
MP
Matthew PfefferBoard director
JW
Jonathan Will McGuireBoard director
TF
TOM FOGERTYBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$64.9M disclosed across 8 rounds · 2011–2021

▶$27.9MraisedApr 2021 · 7 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward SedoExecutive Officer
  • Matthew PfefferDirector
  • Scott DunbarExecutive Officer
  • Gregg WilliamsDirector
  • Aaron MendelsohnDirector
  • Jonathan Will McGuireDirector
Offering amount
$27.9M
Amount sold
$27.9M
Sales commissions
$1.8M
Placement agents
ThinkEquity, a division of Fordham Financial Management, Inc.
First sale
Mar 2021
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedDec 2018 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Aaron MendelsohnDirector
  • Jonathan Will McGuireExecutive Officer, Director
  • Gregg WilliamsDirector
  • Matthew PfefferDirector
  • William LinkDirector
  • John T. BlakeExecutive Officer
Offering amount
$3M
Amount sold
$3M
Minimum investment
$1M
First sale
Dec 2018
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedOct 2018 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Aaron MendelsohnDirector
  • Gregg WilliamsDirector
  • John T. BlakeExecutive Officer
  • Jonathan Will McGuireExecutive Officer, Director
  • William LinkDirector
  • Matthew PfefferDirector
Offering amount
$4M
Amount sold
$4M
Minimum investment
$1M
First sale
Oct 2018
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedAug 2018 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William LinkDirector
  • Gregg WilliamsDirector
  • Matthew PfefferDirector
  • Jonathan Will McGuireExecutive Officer, Director
  • Aaron MendelsohnDirector
  • John T. BlakeExecutive Officer
Offering amount
$5M
Amount sold
$5M
Minimum investment
$1M
First sale
Aug 2018
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedMay 2018 · 1 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Gregg WilliamsDirector
  • John T. BlakeExecutive Officer
  • Matthew PfefferDirector
  • Bill LinkDirector
  • Aaron MendelsohnDirector
  • Jonathan Will McGuireExecutive Officer, Director
Offering amount
$10M
Amount sold
$10M
Minimum investment
$1M
First sale
May 2018
Incorporated
Corporation, California
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$11MraisedJul 2014 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • GREGG WILLIAMSDirector
  • TOM FOGARTYDirector
  • AARON MENDELSOHNDirector
  • WILLIAM LINKDirector
  • ALFRED MANNDirector
  • ROBERT GREENBERGExecutive Officer, Director
  • KATHY LONDONExecutive Officer
Offering amount
$12M
Amount sold
$11M
Minimum investment
$1K
Finders' fees
$150K
Proceeds to insiders
$250K
First sale
Sep 2013
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedFeb 2012 · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • TOM FOGERTYDirector
  • WILLIAM LINKDirector
  • ALFRED MANNDirector
  • AARON MENDELSOHNDirector
  • GREGG WILLIAMSDirector
  • ROBERT GREENBERGExecutive Officer, Director
  • KATHY LONDONExecutive Officer
Offering amount
$2M
Amount sold
$2M
Minimum investment
$2K
First sale
Feb 2012
Incorporated
Corporation, California
Federal exemptions
06
Full filing on SEC EDGAR ↗
▶$2MraisedFeb 2012 · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • AARON MENDELSOHONDirector
  • KATHY LONDONExecutive Officer
  • GREGG WILLIAMSDirector
  • WILLIAM LINKDirector
  • TOM FOGERTYDirector
  • ALFRED MANNDirector
  • ROBERT GREENBERGExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
Minimum investment
$2K
First sale
Dec 2011
Incorporated
Corporation, California
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$85.4Mvaluation at IPOJan 2017 · $1.53/share · S-1/A
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does Second Sight Medical Products do?
Vivani develops miniaturized, long-acting subdermal drug implants using its NanoPortal technology to deliver steady doses of medication over months, addressing medication adherence challenges in chronic disease. Its pipeline targets chronic weight management and type 2 diabetes with semaglutide-based implants.
Who founded Second Sight Medical Products?
Second Sight Medical Products was founded by ALFRED MANN, ROBERT GREENBERG.
Who are Second Sight Medical Products's investors?
Second Sight Medical Products's investors include Versant Venture AIV Holdings.
How much funding has Second Sight Medical Products raised?
Second Sight Medical Products has disclosed $64.9M raised across 8 rounds.
Where is Second Sight Medical Products headquartered?
Second Sight Medical Products is headquartered in Sylmar, US.